Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Core Viewpoint - Soleno Therapeutics, Inc. is facing a securities fraud class action lawsuit due to alleged misrepresentation of safety concerns related to its DCCR drug during clinical trials [3]. Group 1: Lawsuit Details - The lawsuit claims that from March 26, 2025, to November 4, 2026, Soleno failed to disclose significant safety concerns regarding the DCCR drug, particularly issues related to excess fluid retention in trial participants [3]. - The complaint asserts that the administration of DCCR posed materially greater safety risks than what was disclosed by the company and its executives [3]. - It is alleged that DCCR had lower commercial viability and undisclosed risks, including potential adverse events post-launch, which were not communicated to investors [3]. Group 2: Investor Participation - Investors who suffered losses related to Soleno Therapeutics have the opportunity to lead the class action lawsuit, with a deadline for participation set for May 5, 2026 [2]. - Interested investors can contact the Law Offices of Frank R. Cruz for more information on how to participate in the lawsuit [4].